Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Melanocytic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Melanocytic Neoplasm

Cancer Family

Melanocytic Neoplasm

CI-CAN-00000026Explore in graph →

Non-malignant609 active trials13 approved drugs233 evidence items

NCIt: C7058

Overview
Statistics
Survival
Genomics26
Variants & evidence233
Drugs64
Trials3258
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (185)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 76–100 of 185 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
· N Engl J Med · 2012 · PMID 22356324 · validated civic_curation pubmed
Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.
· Histopathology · 2013 · PMID 23802768 · validated civic_curation pubmed
Nivolumab plus ipilimumab in advanced melanoma.
· N Engl J Med · 2013 · PMID 23724867 · validated civic_curation pubmed
Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.
· Pigment Cell Melanoma Res · 2015 · PMID 25515853 · validated civic_curation pubmed
Targeting mutant NRAS signaling pathways in melanoma.
· Pharmacol Res · 2016 · PMID 26987942 · validated civic_curation pubmed
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
· Br J Cancer · 2017 · PMID 28103611 · validated civic_curation pubmed
The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial.
· Contemp Oncol (Pozn) · 2015 · PMID 26557775 · validated civic_curation pubmed

Showing 76–100 of 185 publications

← Previous
1
2
3
4
5
…
8
Next →

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.

· Ann Oncol · 2015 · PMID 25524477 · validated civic_curation pubmed

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

· Cancer Discov · 2014 · PMID 24265155 · validated civic_curation pubmed

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

· Lancet Oncol · 2014 · PMID 25037139 · validated civic_curation pubmed

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.

· J Clin Oncol · 2019 · PMID 31580757 · validated civic_curation pubmed

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.

· PLoS One · 2014 · PMID 24586605 · validated civic_curation pubmed

PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.

· Eur J Cancer · 2015 · PMID 25542057 · validated civic_curation pubmed

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

· Lancet Oncol · 2013 · PMID 23414587 · validated civic_curation pubmed

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

· Lancet Oncol · 2012 · PMID 22805292 · validated civic_curation pubmed

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.

· Clin Cancer Res · 2016 · PMID 26307133 · validated civic_curation pubmed

A phase 2 trial of dasatinib in advanced melanoma.

· Cancer · 2011 · PMID 21523734 · validated civic_curation pubmed

Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.

· J Clin Invest · 2019 · PMID 30835257 · validated civic_curation pubmed

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

· J Clin Oncol · 2013 · PMID 23715574 · validated civic_curation pubmed

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

· Cancer Discov · 2013 · PMID 23288408 · validated civic_curation pubmed

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

· N Engl J Med · 2016 · PMID 27433843 · validated civic_curation pubmed

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

· J Clin Oncol · 2011 · PMID 21383288 · validated civic_curation pubmed

Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3.

· Nat Genet · 2013 · PMID 23793026 · validated civic_curation pubmed

Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.

· Nature · 2015 · PMID 26444240 · validated civic_curation pubmed

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.

· Mol Cancer Ther · 2018 · PMID 29054983 · validated civic_curation pubmed